ClinicalTrials.gg
Active, not recruitingNCT05839301Updated Jun 18, 2023

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

A Phase 3 interventional study of Investigational live attenuated varicella vaccine (lot 1) and Investigational live attenuated varicella vaccine (lot 2) in Varicella, sponsored by China National Biotec Group Company Limited. Active, not recruiting at 1 site in China. Open to participants aged 1 Year to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 3 months ago, but the record still lists the study as active, not recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
1 Year to 12 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Read the detailed description

This trial is aim to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy people 1 to 12 years of age.1200 healthy subjects aged 1-12 years were enrolled after their guardians passed the informed consent, inclusion and exclusion criteria screening in turn. Three batches were randomized in a 1:1: 1 ratio, with 400 subjects in each batch.All subjects received 1 dose of trial vaccine (Batch 1 or Batch 2 or Batch 3) and all were collected Blood samples were collected from subjects before vaccination, on Day 30 after vaccination for serum neutralizing antibody testing to evaluate immunogenicity, and Safety observations were performed until 6 months post-vaccination in all subjects.

02

Conditions studied

  • Varicella

Browse trials for

Keywords

  • varicella vaccine
  • safety
  • immunogenicity
  • lot-to-lot consistency
03

In context

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

This study's enrollment of 1,200 is above the median of 475 across 149 interventional studies indexed under Chickenpox.

Browse Chickenpox studies →

Lead sponsor

China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.

First submitted after China National Biotec Group Company Limited became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 to 12 years on the day of enrollment ,male or female, and able to provide legal identity certificate.
  • Subjects and/or guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the form.
  • Axillary temperature ≤ 37.0 ° C on the day of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination against varicella (eg, varicella vaccine, measles + varicella vaccine).
  • History of varicella or herpes zoster infection, or exposure to varicella/herpes zoster within 30 days of enrollment or suspected varicella/herpes zoster;
  • Current use of salicylates (including salicylic acid, aspirin, diflunisal, p-aminosalicylic acid (sodium), salsalsalate, benorilate, etc.), or planned long-term use during the study.
  • Febrile illness (axillary temperature ≥ 38.5 ° C) or use of antipyretic, analgesic, and anti-allergic drugs (eg, acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination.
  • History of allergy to vaccine ingredients and or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria.
  • History of epilepsy, convulsions, or convulsions, or a family history of psychosis.
  • Impaired immune function or has been diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other diseases.
  • Patients suffering from serious congenital malformations, genetic diseases, serious cardiovascular diseases, serious liver/kidney diseases, diabetes with complications, malignant tumors, severe malnutrition.
  • therapy such as chronic oral or injectable therapy (≥ 14 days at doses ≥ 2 mg/kg/day or ≥ 20 mg/day prednisone or equivalent prednisone dose) within 3 months prior to administration of trial vaccine or planned 30 days following administration, but not limited by topical use (eg, ointment, eye drops, inhalers, or nasal sprays).
  • Receiving blood/blood-related products or immunoglobulins 3 months before vaccination or planning to use such products 30 days after vaccination.
  • Vaccination with a within 30 days or any vaccine within 14 days prior to vaccination.
  • Absence of spleen or splenectomy due to any condition such as splenectomy.
  • Patients with a history of thrombocytopenia or other coagulation disorders, which may cause to subcutaneous injection.
  • Infectious, suppurative and allergic skin diseases.
  • Participating in other or non-registered product (drug, vaccine or device, etc.) clinical trials, or planning to participate in other clinical trials before the end of this clinical trial.
  • Subject has any other factor that, in the judgment of the investigator, would make the subject unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,200 participants (actual)

Study arms

  • Experimental
    Experimental Group1

    Single subcutaneous injection of the investigational vaccine (0.5ml)

    Biological: Investigational live attenuated varicella vaccine (lot 1)

  • Experimental
    Experimental Group2

    Single subcutaneous injection of the investigational vaccine (0.5ml)

    Biological: Investigational live attenuated varicella vaccine (lot 2)

  • Experimental
    Experimental Group3

    Single subcutaneous injection of the investigational vaccine (0.5ml)

    Biological: Investigational live attenuated varicella vaccine (lot 3)

Interventions

  • BiologicalInvestigational live attenuated varicella vaccine (lot 1)

    0.5ml/vial

  • BiologicalInvestigational live attenuated varicella vaccine (lot 2)

    0.5ml/vial

  • BiologicalInvestigational live attenuated varicella vaccine (lot 3)

    0.5ml/vial

06

What researchers measure

Primary outcomes

  1. Geometric mean titers (GMT) of anti-VZV neutralizing antibodies

    Geometric mean titers (GMT) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization

    Time frame: 30 days after vaccination

Secondary outcomes

  1. Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies

    Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization

    Time frame: 30 days after vaccination

  2. Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies

    Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies 30 days after vaccination in the whole population

    Time frame: 30 days after vaccination

  3. The incidences of adverse events (AEs)

    AEs occurred witnin 30 days after vaccination will be collected

    Time frame: 30 days after vaccination

  4. The incidences of serious adverse events (SAEs) and Adverse Event of Special Interest(AESI)

    SAEs and AESI occurred witnin 6 months after vaccination will be collected

    Time frame: 6 months after vaccination

07

Study locations

1 site
  • Xinyi Center for Disease Control and Prevention
    Xuzhou, Jiangsu 221600, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05839301
Collaborators
Beijing Institute of Biological Products Co Ltd., Jiangsu Province Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Apr 27, 2023
Primary completion
Jul 30, 2023 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Jun 18, 2023

Study contacts

Hongxing Pan
principal investigator · Jiangsu Province Centers for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion